Curis, Inc...announced that it will host a webcast on Wednesday, July 22 at 8:30 a.m. ET to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL) (Curis Press Release) - Jul 22, 2026 - "Take Aim Lymphoma: The PCNSL update includes data for 7 BTK-naive patients and 39 BTKi-experienced patients...BTKi-naive evaluable patients (100% ORR); BTKi-naive all patients (86% ORR); BTKi-naive previous data patients (71% ORR). BTKi-experienced evaluable patients (33% ORR); BTKi-experienced all patients (26% ORR); BTKi-experienced previous data patients (27% ORR)."
P1/2 data • CNS Lymphoma • Primary Central Nervous System Lymphoma
|